FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage
ConditionAneurysmal Subarachnoid Hemorrhage
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorThe George Institute
About this trial
A multi-centre, prospective, blinded, randomised clinical trial of fludrocortisone compared with placebo in patients presenting with aneurysmal subarachnoid haemorrhage.
The study aim is to determine if early administration of enteral fludrocortisone in aneurysmal subarachnoid haemorrhage reduce death and dependency at six months.
Eligibility criteria
Qualifiers
Age 18 years or older
Diagnosed with subarachnoid haemorrhage from an aneurysm confirmed on computed tomography angiography (CTA) or digital subtraction angiography (DSA) of the intra-cranial arteries
Aneurysm has been secured
Hospital admission for aSAH within 96 hours
Disqualifiers
Unable to receive enteral medications
Pre-existing glucocorticoid or mineralocorticoid treatment
Previous allergic reaction to fludrocortisone
History of cardiac, hepatic, or renal failure
Trial design
Treatments tested in this trial
- Fludrocortisone
- Placebo
Treatment groups
524 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov